References of "GROSCH, Stéphanie"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailLa glomérulonéphrite fibrillaire non amyloïde : une cause rare de syndrome néphrotique
GROSCH, Stéphanie ULg; VAN OVERMEIRE, Lionel ULg; Krzesinski, Jean-Marie ULg et al

in Néphrologie & Thérapeutique (2011), 7

La glomérulonéphrite fibrillaire non amyloïde est une pathologie glomérulaire à dépôts fibrillaires, non amyloïdes, composés principalement d'immunoglobulines G polyclonales. Il s'agit d'une ... [more ▼]

La glomérulonéphrite fibrillaire non amyloïde est une pathologie glomérulaire à dépôts fibrillaires, non amyloïdes, composés principalement d'immunoglobulines G polyclonales. Il s'agit d'une glomérulopathie idiopathique responsable de protéinurie sévère, souvent néphrotique et d'insuffisance rénale arrivant à un stade terminal dans 40% des cas à cinq ans. Elle peut prendre différents aspects anatomopathologiques déterminants en terme de pronostic rénal. La négativité des dépôts en coloration rouge Congo et l'épaisseur des fibrilles en microscopie électronique permettent le diagnostic différentiel avec les dépôts amyloïdes. Il n'y a pas de traitement efficace. Après transplantation rénale, la récidive est fréquente avec un pronostic rénal cependant moins péjoratif. [less ▲]

Detailed reference viewed: 51 (0 ULg)
Full Text
Peer Reviewed
See detailL'observance thérapeutique en transplantation d'organe - L'exemple de la greffe de rein
Milicevic, Martina ULg; Grosch, Stéphanie ULg; Weekers, Laurent ULg et al

in Revue Médicale de Liège (2010), 65(5-6), 386-390

A successful transplantation implies that immunosuppressive drugs will have to be taken during the whole patient’s life. Poor drug compliance is a multifactorial problem, that is particularly dangerous in ... [more ▼]

A successful transplantation implies that immunosuppressive drugs will have to be taken during the whole patient’s life. Poor drug compliance is a multifactorial problem, that is particularly dangerous in organ transplantation as it can lead to loss of graft function and return to dialysis treatment. The medical doctor must stimulate the patient’s adherence to the strict therapeutic drug protocol. The patient must also be reminded at each medical consultation of the importance of such rigorous drug intake. This bad (or non) compliance is particularly well demonstrated a long time after transplantation. The medical staff, all the health participants, but also the family members must continuously fight against non compliance, which is inherent to any chronic disease. [less ▲]

Detailed reference viewed: 130 (3 ULg)
Full Text
Peer Reviewed
See detailLes anticorps monoclonaux en transplantation rénale
Bonvoisin, Catherine ULg; Weekers, Laurent ULg; Grosch, Stéphanie ULg et al

in Revue Médicale de Liège (2009), 64(5-6), 287-292

Renal transplantation is the best treatment for end-stage renal disease, but requires efficient immunosuppressive therapy. The latter has evolved over recent years with the development of more powerful ... [more ▼]

Renal transplantation is the best treatment for end-stage renal disease, but requires efficient immunosuppressive therapy. The latter has evolved over recent years with the development of more powerful drugs and of monoclonal antibodies with very specific target. The first monoclonal antibodies, acting against the interleukin 2 receptor, named basiliximab and daclizumab, have showed an excellent tolerance profile and efficacy to reduce acute graft rejection. However, in spite of these properties, the development of delayed graft function or the graft and patient survivals at 1 year were not modified by the use of such specific treatment. One potential advantage could yet be a decreasing need for corticosteroids and sometimes calcineurin inhibitors which could provide some long term benefits for the renal graft, but also the patient. Alemtuzumab, another monoclonal antibody, aimed at the membrane glycoprotein CD52, can also decrease the incidence of acute rejection and the depth of the required immunosuppressive therapy. Other antibodies are still in development with some interesting preliminary results which however demand confirmation in larger studies. [less ▲]

Detailed reference viewed: 44 (1 ULg)
Full Text
Peer Reviewed
See detailPolyomavirus in Renal Transplantation: A Hot Problem
Bonvoisin, Catherine ULg; Weekers, Laurent ULg; Xhignesse, Patricia ULg et al

in Transplantation (2008), 85(7S), 42-48

Polyomavirus BK has emerged as an important complication after kidney transplantation. Although, BK nephropathy develops in only1%to5%of renal transplant recipients, its prognosis when present is very ... [more ▼]

Polyomavirus BK has emerged as an important complication after kidney transplantation. Although, BK nephropathy develops in only1%to5%of renal transplant recipients, its prognosis when present is very poor. The most accepted risk factor is the level of immunosuppressive treatment, but the serostatus of donor and recipient and the absence of human leukocyte antigen C7 in donor and/or recipient influence the BK virus (BKV) reactivation. The gold standard in diagnosing BKV nephropathy (BKVN) continues to be biopsy with use of immunohistochemistry for large T antigens. Urinary decoy cells and blood BKV DNA polymerase chain reaction are used in the screening, but their positive predictive values are poor. However, their use as predictors of the evolution of BKVN is more valuable. The reduction of immunosuppressive therapy currently represents the first-line treatment for BKVN. Cidofovir and leflunomide can be used when BKVN continues to progress. In the event of graft loss, retransplantation is possible with a low risk of recurrence when the infection is no longer active. [less ▲]

Detailed reference viewed: 55 (6 ULg)
Full Text
Peer Reviewed
See detailIs cystatin C useful for the detection and the estimation of low glomerular filtration rate in heart transplant patients?
Delanaye, Pierre ULg; Nellessen, Eric ULg; Cavalier, Etienne ULg et al

in Transplantation (2007), 83(5), 641-644

Although previously studied in patients with chronic kidney disease, there is less data for the use of cystatin C and cystatin C-based formulas in heart transplant recipients. The ability of creatinine ... [more ▼]

Although previously studied in patients with chronic kidney disease, there is less data for the use of cystatin C and cystatin C-based formulas in heart transplant recipients. The ability of creatinine and cystatin C to detect renal failure (glomerular filtration rate [GFR] below 60 mL/min/1.73 m(2)) in heart transplant patients has been compared. The accuracy and precision of a creatinine-based formula (Modification of Diet in Renal Disease [MDRD]) versus a cystatin C-based formula (Rule's formula) to estimate GFR have also been studied. GFR was measured using the (51)Crethylenediamine tetraacetic acid tracer in 27 patients. There was no significant difference between GFR and the reciprocal of creatinine or cystatin C. Receiver operating characteristic curves for cystatin C and creatinine were similar. Both formulas were well correlated with the GFR. The bias of the cystatin C-based was significantly better than one of the MDRD formula, but the standard deviation appeared better for the MDRD formula (bias of +3.9 mL/min/1.73 m(2) versus +12 mL/min/1.73 m(2) and SD of 8.5 versus 11.6, respectively). Plasma cystatin C has no clear advantage over serum creatinine to detect renal failure in heart transplanted patients. [less ▲]

Detailed reference viewed: 31 (4 ULg)
Full Text
Peer Reviewed
See detailCreatinine-based formulae for the estimation of glomerular filtration rate in heart transplant recipients
Delanaye, Pierre ULg; Nellessen, Eric ULg; Grosch, Stéphanie ULg et al

in Clinical Transplantation (2006), 20(5, Sep-Oct), 596-603

Chronic renal failure (CRF) is a common complication in heart transplant patients. Serum creatinine has clear limitations for the detection and estimation of glomerular filtration rate (GFR). Various ... [more ▼]

Chronic renal failure (CRF) is a common complication in heart transplant patients. Serum creatinine has clear limitations for the detection and estimation of glomerular filtration rate (GFR). Various creatinine-based formulae are classically used for GFR estimation, but little scientific evidence exists for such use in a heart transplant population. GFR was measured using the plasmatic clearance of the glomerular tracer Cr-51-EDTA in 27 heart transplant patients with two measures for 22 of the patients. Forty-nine measures were thus available for analysis. The precision and accuracy (Bland and Altman analysis) of the Cockcroft, simplified Modified Diet in Renal Diseases (MDRD) and new Mayo Clinic formulae were compared. The mean GFR of the population was 39 +/- 15 mL/min/1.73 m(2). All formulae were well correlated with the GFR. With the Bland and Altman analysis, the accuracy of the MDRD formula appeared higher than that of the Cockcroft or the Mayo Clinic formulae (bias of +12 mL/min/1.73 m(2), vs. +19.9 mL/min/1.73 m(2), and +22.1 mL/min/1.73 m(2), respectively). The difference between the estimated and measured GFR was higher than 20 mL/min/1.73 m(2) in 51% and 55% cases when using the Cockcroft and the Mayo Clinic formulae respectively, whereas the difference was only noted in 14% cases when the MDRD was used. Among creatinine-based formulae, the MDRD appears the most precise and accurate for estimating the GFR in heart transplant patients. However, when the GFR must be measured with high accuracy, we recommend the use of a reference method like inulin or Cr-51-EDTA plasma clearance techniques. [less ▲]

Detailed reference viewed: 40 (4 ULg)
Full Text
Peer Reviewed
See detailAttitude à adopter devant une pression artérielle chroniquement basse
Grosch, Stéphanie ULg; Maillet, J.; Krzesinski, Jean-Marie ULg

in Revue Médicale de Liège (2006), 61(5-6, May-Jun), 374-9

Chronic arterial hypotension has been poorly studied. Its mechanisms are not well understood; its treatment (if needed) is disappointing, without any demonstrated improvement of symptoms or prognosis ... [more ▼]

Chronic arterial hypotension has been poorly studied. Its mechanisms are not well understood; its treatment (if needed) is disappointing, without any demonstrated improvement of symptoms or prognosis. Thus, a complete medical examination is needed to exclude any organic cause. If none is found, it is important to reassure the patient and to convince him not to use expensive drugs potentially generative of side effects. [less ▲]

Detailed reference viewed: 93 (2 ULg)
Full Text
Peer Reviewed
See detailVariabilité de la pression artérielle: curiosité naturelle ou phénomène à maitriser?
Grosch, Stéphanie ULg; Saint-Remy, Annie ULg; Krzesinski, Jean-Marie ULg

in Revue Médicale de Liège (2005), 60(3), 147-53

Blood pressure variability is a physiological phenomenon influenced by many internal and external factors. This variability could be also influenced by pathological conditions such as arterial ... [more ▼]

Blood pressure variability is a physiological phenomenon influenced by many internal and external factors. This variability could be also influenced by pathological conditions such as arterial hypertension. Two forms must be mainly distinguished: the blood pressure variability at long but also short-term. The latter could only be studied by continuous recordings. From the initial invasive intraarterial approach, it can nowadays be explored by a non invasive system of beat to beat recordings using the infrared photo plethysmography (the FINAPRES system). In this paper, some important questions will be treated such as the interest of measuring blood pressure variability, its cardiovascular prognosis and how therapeutic tools can be applied when it is increased? [less ▲]

Detailed reference viewed: 207 (2 ULg)